Diabetes Care, Vol 23, Issue 6 807-812, Copyright © 2000 by American Diabetes Association

ARTICLES

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1

T Vilsboll, MB Toft-Nielsen, T Krarup, S Madsbad, B Dinesen and JJ Holst
Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. tivi@gentoftehosp.kbhamt.dk

OBJECTIVE: Beta-cell secretory capacity is often evaluated with a glucagon test or a meal test. However, glucagon-like peptide 1 (GLP-1) is the most insulinotropic hormone known, and the effect is preserved in type 2 diabetic patients. RESEARCH DESIGN AND METHODS: We first compared the effects of intravenous bolus injections of 2.5, 5, 15, and 25 nmol GLP-1 with glucagon (1 mg intravenous) and a standard meal (566 kcal) in 6 type 2 diabetic patients and 6 matched control subjects. Next, we studied another 6 patients and 6 control subjects and, in addition to the above procedure, performed a combined glucose plus GLP-1 stimulation, where plasma glucose was increased to 15 mmol/l before injection of 2.5 nmol GLP-1. Finally, we compared the insulin response to glucose plus GLP-1 stimulation with that observed during a hyperglycemic arginine clamp (30 mmol/l) in 8 patients and 8 control subjects. RESULTS: Peak insulin and C-peptide concentrations were similar after the meal, after 2.5 nmol GLP-1, and after glucagon. Side effects were less with GLP-1 than with glucagon. Peak insulin and C-peptide concentrations were as follows (C-peptide concentrations are given in parentheses): for patients (n = 12): meal, 277 +/- 42 pmol/l (2,181 +/- 261 pmol/l); GLP-1 (2.5 nmol), 390 +/- 74 pmol/l (2,144 +/- 254 pmol/l); glucagon, 329 +/- 50 pmol/l (1,780 +/- 160 pmol/l); glucose plus GLP-1, 465 +/- 87 pmol/l (2,384 +/- 299 pmol/l); for control subjects (n = 12): meal, 543 +/- 89 pmol/l (2,873 +/- 210 pmol/l); GLP-1, 356 +/- 51 pmol/l (2,001 +/- 130 pmol/l); glucagon, 420 +/- 61 pmol/l (1,995 +/- 99 pmol/l); glucose plus GLP-1, 1,412 +/- 187 pmol/l (4,391 +/- 416 pmol/l). Peak insulin and C-peptide concentrations during the hyperglycemic arginine clamp and during glucose plus GLP-1 injection were as follows: for patients: 475 +/- 141 pmol/l (2,295 +/- 379 pmol/l) and 816 +/- 268 pmol/l (3,043 +/- 508 pmol/l), respectively; for control subjects: 1,403 +/- 308 pmol/l (4,053 +/- 533 pmol/l) and 2,384 +/- 452 pmol/l (6,047 +/- 652 pmol/l), respectively. CONCLUSIONS: GLP-1 (2.5 nmol = 9 microg) elicits similar secretory responses to 1 mg glucagon (but has fewer side effects) and a standard meal. Additional elevation of plasma glucose to 15 mmol/l did not enhance the response further. The incremental response was similar to that elicited by arginine, but hyperglycemia had an additional effect on the response to arginine.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Vilsboll, F. K. Knop, T. Krarup, A. Johansen, S. Madsbad, S. Larsen, T. Hansen, O. Pedersen, and J. J. Holst The Pathophysiology of Diabetes Involves a Defective Amplification of the Late-Phase Insulin Response to Glucose by Glucose-Dependent Insulinotropic Polypeptide--Regardless of Etiology and Phenotype J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4897 - 4903. [Abstract] [Full Text] [PDF]

				L. L. Kjems, J. J. Holst, A. Volund, and S. Madsbad The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on {beta}-Cell Sensitivity in Type 2 and Nondiabetic Subjects Diabetes, February 1, 2003; 52(2): 380 - 386. [Abstract] [Full Text] [PDF]

				T. Vilsboll, H. Agerso, T. Krarup, and J. J. Holst Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 220 - 224. [Abstract] [Full Text] [PDF]

				M. O. Larsen, B. Rolin, M. Wilken, R. D. Carr, and C. F. Gotfredsen Measurements of Insulin Secretory Capacity and Glucose Tolerance to Predict Pancreatic {beta}-Cell Mass In Vivo in the Nicotinamide/Streptozotocin Gottingen Minipig, a Model of Moderate Insulin Deficiency and Diabetes Diabetes, January 1, 2003; 52(1): 118 - 123. [Abstract] [Full Text] [PDF]